In 2025, Russians purchased nearly 10.4 million packages of antifungal drugs for the treatment of gynecological diseases (G01B – according to the EphMRA classifier) on the retail market, amounting to RUB 5.8 billion (at retail prices, including VAT). The monetary sales volume for this group increased by 8.5% over the year. Notably, ruble growth in this category has been observed for the third consecutive year, and last year it was driven exclusively by the rising cost of the drugs purchased, which has been increasing by 10% for two years in a row. At the same time, physical consumption declined for the first time in several years – sales in packages decreased by 1.3% compared to 2024.

In January of this year, demand for this drug group also fell significantly – compared to the first month of 2025, sales decreased by 5% in rubles and by 11% in packages. Over the month, Russians purchased about 786,000 packages of such products, worth over RUB 440.8 million. The highest physical consumption volumes in the past year were observed in October – during that month, buyers purchased over 908,000 packages, spending RUB 518.7 million. The minimum for the category was recorded in June, when 812,300 packages worth RUB 454 million were sold through pharmacies.

According to the database "Retail Audit of Medicinal Products Sales in Russia (total sell out)" from the analytical company RNC Pharma, in 2025, retail offered 11 INNs and 28 trademarks, with only two new brands appearing on the market in the last three years. Both are vaginal suppositories based on sertaconazole (Flucovag from Otcpharm) and natamycin (Natafucin from Salvus).

The largest expenditures by Russians within the group were directed towards the combined drug Polygynax, from Innotec, which contains both antifungal and antibacterial components (23.3% share in rubles) – its sales increased by 8% in rubles over the year, but physical consumption of the brand is falling, with sales down 3.9% compared to 2024. In second and third positions are products containing acidophilic lactobacilli from Besins Healthcare under the brand Lactoginal, and Gynoflor E from Gedeon Richter – the brands hold shares of 15.9% and 13.2% in rubles, respectively. While sales of Lactoginal decreased over the year (-3.8% in rubles), sales of Gynoflor E grew by 47.5% during this period; this was, incidentally, the highest growth rate among top products in the reporting period.

Outside the top tier, the maximum growth was noted for the drug Primafungin (INN natamycin) in the form of vaginal suppositories from Avexima. Compared to 2024, the brand's physical sales increased by 50%, and its monetary volume grew by 60%.

Table. TOP-10 Brand Names of Antifungal Drugs for the Treatment of Gynecological Diseases (Group G01B – according to the EphMRA classifier), by Monetary Sales Volume on the Russian Retail Pharmaceutical Market in 2025